While Alzheimer’s remains a complex disease, recent clinical trials and research efforts have expanded, emphasizing biomarkers and better patient targeting to improve drug development success rates.
How close are we to an Alzheimer’s cure? A Kirk Kerkorian School of Medicine at the University of Nevada Las Vegas (UNLV) expert, Jeffrey L. Cummings M.D., ScD, has published an analysis of recent progress towards this goal, according to an announcement.
Dr. Cummings told UNLV that the disease is no longer untreatable. His report highlighted the following advancements:
40% more Alzheimer’s therapies have been tested in the last decade.
There are 59 more drug trials since last year.
Research targeting amyloids has steadied, while drug developers are looking to inflammation/immune targeting drugs more.
Clinical trials cover all stages of the disease.
Dr. Cummings concluded his analysis with a call for more research. He said, “Better target identification, improved ascertainment of potentially responsive patient populations, enhanced use of biomarkers to inform understanding of drug effects, and more stringent criteria for advancing drugs to late-stage development are anticipated to improve the success rate of AD drug development.”
